[go: up one dir, main page]

ES2156199T3 - Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma. - Google Patents

Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.

Info

Publication number
ES2156199T3
ES2156199T3 ES95308055T ES95308055T ES2156199T3 ES 2156199 T3 ES2156199 T3 ES 2156199T3 ES 95308055 T ES95308055 T ES 95308055T ES 95308055 T ES95308055 T ES 95308055T ES 2156199 T3 ES2156199 T3 ES 2156199T3
Authority
ES
Spain
Prior art keywords
interferon
gamma
prevention
treatment
polipeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95308055T
Other languages
English (en)
Other versions
ES2156199T5 (es
Inventor
Shimpei Ushio
Kakuji Torigoe
Tadao Tanimoto
Haruki Okamura
Toshio Kunikata
Mutsuko Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
Hayashibara Biochemical Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27523434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2156199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP7058240A external-priority patent/JP2952750B2/ja
Priority claimed from JP7262062A external-priority patent/JP2724987B2/ja
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK, Hayashibara Biochemical Laboratories Co Ltd filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Publication of ES2156199T3 publication Critical patent/ES2156199T3/es
Application granted granted Critical
Publication of ES2156199T5 publication Critical patent/ES2156199T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UN POLIPEPTIDO QUE TIENE UN PESO MOLECULAR DE 18,500 (MAS MENOS) 3,000 DALTONS EN SDS-PAGE Y UN PL DE 4.9 (MAS MENOS) 1.0 SOBRE CROMATOENFOCADO. EL POLIPEPTIDO INDUCE FUERTEMENTE LA PRODUCCION DE IFN-{GA} POR CELULAS INMUNOCOMPETENTES CON SOLAMENTE UNA PEQUEÑA CANTIDAD, Y NO PROVOCA SERIOS EFECTOS COLATERALES INCLUSO CUANDO SE ADMINISTRA A LOS HUMANOS EN UNAS DOSIS RELATIVAMENTE ALTAS. SE PREPARA UTILIZANDO UN ANTICUERPO MONOCLONAL OBTENIDO A PARTIR DE HIBRIDOMAS, Y SE INCORPORA EN AGENTES PARA EL TRATAMIENTO Y/O LA PREVENCION DE TUMORES MALIGNOS, ENFERMEDADES VIRALES, ENFERMEDADES POR INFECCION BACTERIANA Y ENFERMEDADES INMUNES.
ES95308055T 1994-11-15 1995-11-10 Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma. Expired - Lifetime ES2156199T5 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP6-304203 1994-11-15
JP30420394 1994-11-15
JP7058240A JP2952750B2 (ja) 1995-02-23 1995-02-23 モノクローナル抗体
JP7-58240 1995-02-23
JP7-78357 1995-03-10
JP7835795 1995-03-10
JP7-262062 1995-09-18
JP7262062A JP2724987B2 (ja) 1994-11-15 1995-09-18 インターフェロン−γの産生を誘導するポリペプチド
JP7-274988 1995-09-29
JP27498895 1995-09-29

Publications (2)

Publication Number Publication Date
ES2156199T3 true ES2156199T3 (es) 2001-06-16
ES2156199T5 ES2156199T5 (es) 2006-12-16

Family

ID=27523434

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95308055T Expired - Lifetime ES2156199T5 (es) 1994-11-15 1995-11-10 Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
ES99104104T Expired - Lifetime ES2329099T3 (es) 1994-11-15 1995-11-10 Fragmento polipeptidico aislado que induce produccion de interferon-gamma y un fragmento de adn aislado que codifica dicho polipeptido.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99104104T Expired - Lifetime ES2329099T3 (es) 1994-11-15 1995-11-10 Fragmento polipeptidico aislado que induce produccion de interferon-gamma y un fragmento de adn aislado que codifica dicho polipeptido.

Country Status (7)

Country Link
EP (2) EP0712931B2 (es)
AU (1) AU700948B2 (es)
CA (1) CA2162353C (es)
DE (2) DE69520088T3 (es)
DK (2) DK0962531T3 (es)
ES (2) ES2156199T5 (es)
TW (2) TW581771B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135458B1 (en) 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
JP4004088B2 (ja) * 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
CA2238885A1 (en) * 1995-12-29 1997-07-10 Incyte Pharmaceuticals, Inc. Nucleic acids encoding interferon gamma inducing factor-2
AU3116697A (en) * 1996-05-20 1997-12-09 Schering Corporation Human interleukin-1j and antagonists thereof
EP0816499A3 (en) * 1996-06-27 1999-10-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
US6790442B1 (en) 1996-06-27 2004-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ
JPH1080270A (ja) * 1996-07-19 1998-03-31 Hayashibara Biochem Lab Inc ポリペプチドをプロセッシングする酵素
TW515843B (en) * 1996-07-25 2003-01-01 Hayashibara Biochem Lab Process for producing an active polypeptide inducing interferon-γ production
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP3955352B2 (ja) 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
WO1999007851A1 (en) * 1997-08-07 1999-02-18 Toray Industries, Inc. CANINE INTERLEUKIN 18, CANINE INTERLEUKIN 1β CONVERTASE, DNA SEQUENCES ENCODING THE SAME, PROCESS FOR PRODUCING INTERLE UKIN 18, AND REMEDIES FOR CANINE IMMUNOLOGICAL DISEASES
AU751524B2 (en) * 1997-11-03 2002-08-22 Trustees Of The University Of Pennsylvania, The Method and compositions for inhibiting angiogenesis and treating cancer
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US6432678B1 (en) * 1999-06-21 2002-08-13 Smithkline Beecham Corporation Macaca cynomolgus IL 18
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
GB0009503D0 (en) * 2000-04-17 2000-06-07 Univ Liverpool Screening method for compounds
CA2411354A1 (en) * 2000-06-02 2001-12-13 Smithkline Beecham Corporation Methods of treating viral diseases with il-18 and il-18 combinations
WO2001098455A2 (en) 2000-06-15 2001-12-27 Smithkline Beecham Corporation Method for preparing a physiologically active il-18 polypeptide
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
WO2003057821A2 (en) * 2001-10-26 2003-07-17 Centocor, Inc. Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
DE602004025799D1 (de) 2003-04-15 2010-04-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
MX2007002134A (es) 2004-08-20 2007-09-14 Smithkline Beecham Corp Metodos para curar heridas administrando interleucina-18 humana.
KR101416078B1 (ko) 2006-05-25 2014-07-07 글락소 그룹 리미티드 변형된 인간화 항­인터루킨­１８ 항체
AR065803A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
US8168165B2 (en) 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
SG182783A1 (en) 2010-02-09 2012-09-27 Glaxo Group Ltd Treatment of a metabolic disorder
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
AU2015300006B2 (en) 2014-08-07 2018-08-30 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
JP3230531B2 (ja) * 1991-08-08 2001-11-19 光信 佐藤 ＩＦＮ―γ誘導活性物質
EP0692536B1 (en) * 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same

Also Published As

Publication number Publication date
EP0962531A3 (en) 1999-12-15
EP0712931B1 (en) 2001-02-14
EP0962531B1 (en) 2009-08-05
EP0712931B2 (en) 2006-04-19
DE69535989D1 (de) 2009-09-17
EP0962531A2 (en) 1999-12-08
ES2329099T3 (es) 2009-11-20
DK0962531T3 (da) 2009-10-05
DE69520088T3 (de) 2006-11-23
AU700948B2 (en) 1999-01-14
AU3779695A (en) 1996-05-23
DE69520088D1 (de) 2001-03-22
EP0712931A2 (en) 1996-05-22
EP0712931A3 (en) 1997-03-26
CA2162353A1 (en) 1996-05-16
DK0712931T3 (da) 2001-03-19
TW581771B (en) 2004-04-01
DE69520088T2 (de) 2004-07-29
CA2162353C (en) 2010-04-27
TW464656B (en) 2001-11-21
DK0712931T4 (da) 2006-08-21
ES2156199T5 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
ES2156199T3 (es) Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
ES8500997A1 (es) Un metodo para producir un peptido.
BR9915852A (pt) Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MX9203072A (es) Asialoglucoproteina-agente conjugado medicinal.
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
DK0588578T3 (da) Immunogener
ES2075440T3 (es) Vacuna contra la hepatitis b.
CO5300414A1 (es) Composiciones de vacunas con antigenos de streptococus de virus vsr y adyuvante estimulador de respuesta th1
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
ATE205881T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DK0714307T3 (da) Vaccinesammensætninger
KR920004422A (ko) Hiv의 주요 중화 결정인자
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
ES2060695T3 (es) Concentrados terapeuticos de igm.
PT871738E (pt) Particulas virais recombinantes e aplicacoes vacinais e antitumorais
DE69126486D1 (de) Induzierung eines schutzes gegen virale infektionen
ES2194412T3 (es) Uso de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de vasculitis resistente al tratamiento.
ATE133074T1 (de) Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
Gotohda et al. Effect of combination treatment with cyclophosphamide and nonspecific passive immunization on a transplantable tumor in WKA rats
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 712931

Country of ref document: ES